ROTOP has been growing faster than the market for years and supplies around one million patients a year with its products. The increasing demand is leading to space bottlenecks and makes expansion absolutely essential. The new cluster for production and development will create a site that both strengthens technetium-based diagnostics and creates new capacities for the booming theranostics market. The growth is supported by medium-sized investors from Germany who share ROTOP's long-term ambition. The company emphasises that radiopharmaceuticals play a systemically relevant role in modern oncology and should be given greater political support.
ROTOP is also working on a new diagnostic tracer for prostate cancer, which should offer a cost-effective alternative to existing procedures in the future. As part of the anniversary celebrations, the founder Monika Johannsen was honoured and the importance of the Rossendorf site for the radiopharmacy of tomorrow was emphasised with prominent guests from politics and science.
Press release of "ROTOP Pharmaka GmbH" from 21 November 2025